For most of history, menstrual blood has been dismissed as biological waste. But emerging research is now recasting this material as a goldmine for non-invasive diagnostics and regenerative medicine. Its potential applications are surprisingly broad, ranging from innovative cervical cancer screenings to advanced cartilage repair.
Scientists are now digging into these biomarkers hoping to find ways to detect diseases early, and thus drop the use of invasive clinical procedures. The team found that menstrual blood collected directly from sanitary pads could be tested for human papillomavirus DNA and precancerous lesions just as accurately as cervical swab samples collected by a clinician. Of course, the method excludes those who do not menstruate, but the fact that it offered a non-invasive, inexpensive, and suitable test that could begin from home is notable. Menstrual blood is also gaining research focus thanks to stem cells derived from it. These cells came from the endometrium, the uterine lining that breaks down and rebuilds itself on a monthly cycle without scarring — something other human tissue cannot do. The researchers believed the stem cells had something to do with that ability. In the lab, the menstrual-blood-derived stem cells readily divided and proved to be tough and versatile.
In 2025, a large population-based study in The BMJ by researchers from China offered a workaround. The groundwork for this was laid back in 2007 when a team from the U.S. and Canada successfully isolated menstrual stem cells from menstrual blood.
Scientists do not yet know how long these cells will survive once they are introduced into the body. Researchers are already using them to grow uterine organoids — small functional models of the uterus located outside the body and used to study conditions like endometriosis. As the science of these cells has matured, so have their applications. This is a rare and devastating inherited condition that is caused by cholesterol and lipids build-up inside cells, leading to rapid neurological decline, loss of motor function, and dementia. The study found that menstrual-blood-derived stem cells could significantly lower neuroinflammation and cell death in experimental models of the disease. The work is still in its early stages, but for a condition whose therapeutic options are currently limited to drugs easing the clinical symptoms, a potential new advance is welcome. Some significant hurdles remain as well. Producing consistent, high-quality batches also remains a challenge, since no standardised benchmarks exist to verify the cells before use. The cells must themselves behave differently depending on the donor, varying with age, hormonal status, contraceptive history, and the conditions in which the cells were grown in the lab.
Because there are no reliable markers to track the cells once they are inside a patient, there is no long-term human safety data— partly. For instance, in 2025, a team in China studied the role they could play on Niemann-Pick disease type C1. A 2023 study by Iranian researchers showed that when these cells were delivered alongside their conditioned medium — the nutrient-rich fluid they had been cultured with — they helped accelerate heart recovery in rat models after a heart attack.
The stem cells could reveal traces of exposure to chemical compounds like phthalates and parabens, which was previously not possible to discern without an invasive examination.
